![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Vitreous -Retina- Macula Consultants of New York Genentech |
---|---|
Information provided by: | Vitreous -Retina- Macula Consultants of New York |
ClinicalTrials.gov Identifier: | NCT00403156 |
The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.
Condition | Intervention | Phase |
---|---|---|
Choroidal Neovascularization |
Drug: Imatinib Mesylate /Ranibizumab |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase I Study of the Inhibition of Platelet Derived Growth Factor Using Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration |
Estimated Enrollment: | 15 |
Study Start Date: | November 2006 |
This is an open-label dose escalating study (n=15) to evaluate the safety and tolerability of the addition of imatinib mesylate to the Lucentis treatment regime over a 6 month period in patients with newly diagnosed choroidal neovascularization:
Ages Eligible for Study: | 51 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
For occult with no classic CNV, the lesion must have presumed recent disease progression as assessed by the Investigator and defined as having at least one of the following criteria:
Exclusion Criteria:
United States, New York | |
Vitreous Retina Macula Consultants of New York, P.C. | |
New York, New York, United States, 10022 |
Principal Investigator: | Richard F. Spaide, M.D. | Vitreous Retina Macula Consultants of New York, P.C. |
Responsible Party: | Vitreous Retina Macula Consultants of New York ( Richard Spaide, MD ) |
Study ID Numbers: | FVF3989S |
Study First Received: | November 22, 2006 |
Last Updated: | November 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00403156 |
Health Authority: | United States: Food and Drug Administration |
Macular Degeneration |
Imatinib Metaplasia Eye Diseases Choroid Diseases Neoplasm Metastasis Retinal Degeneration |
Macular Degeneration Neovascularization, Pathologic Retinal Diseases Retinal degeneration Choroidal Neovascularization |
Uveal Diseases Pathologic Processes Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Therapeutic Uses Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions |